Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | 0.59% | 63.00 | 1.0% | $429.15m | |
| AMGN | Amgen, Inc. | -1.61% | 237.60 | 1.3% | $415.39m | |
| BIIB | Biogen, Inc. | 0.59% | 287.19 | 1.4% | $362.99m | |
| ILMN | Illumina, Inc. | 1.11% | 328.33 | 3.5% | $323.56m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -0.78% | 233.99 | 1.9% | $273.36m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -5.76% | 363.71 | 2.6% | $217.27m | |
| EXAS | EXACT Sciences Corp. | -2.45% | 85.90 | 24.0% | $197.11m | |
| ITCI | Intra-Cellular Therapies, Inc. | -3.12% | 25.43 | 9.0% | $173.46m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -0.23% | 113.01 | 2.0% | $173.06m | |
| INCY | Incyte Corp. | -2.30% | 78.65 | 2.5% | $135.12m | |
| SRPT | Sarepta Therapeutics, Inc. | -3.84% | 122.99 | 14.6% | $133.04m | |
| A | Agilent Technologies, Inc. | -0.56% | 89.62 | 1.6% | $120.06m | |
| BMRN | BioMarin Pharmaceutical, Inc. | -0.82% | 87.55 | 4.3% | $106.16m | |
| BLUE | bluebird bio, Inc. | -2.26% | 95.82 | 14.2% | $95.27m | |
| SGEN | Seattle Genetics, Inc. | -0.30% | 108.67 | 6.1% | $90.33m |
Company Profile
Clovis Oncology, Inc. is a commercial stage biotechnology company, which engages in the acquisition, development, and commercialization of cancer treatments in the United States, Europe, and other markets. Its product development programs target specific subsets of cancer, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from its use. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.